Tag: Anticoagulants
Ticagrelor-Acetylsalicylic Acid More Beneficial for Obese With Minor Stroke, TIA
Significantly lower rate of stroke within 90 days seen for ticagrelor-ASA versus clopidogrel-ASA for those carrying CYP2C19 loss-of-function allele
Anticoagulants Do Not Reduce Arterial Thrombotic Event Risk in Cancer
No reduction seen in risk of antithrombotic events but increased risk of major and minor bleeding
Benefits of Indefinite Anticoagulant Unclear After First VTE
Indefinite anticoagulation prevented recurrent VTE events, but induced major bleeding events
Catheter-Directed Thrombolysis Beneficial for Pulmonary Embolism
Systematic review showed risk for death and major bleeding complications was lower for catheter-directed thrombolysis than systemic thrombolysis
ASCO: Direct Oral Anticoagulant Therapy Feasible for Cancer Patients
Direct oral anticoagulants noninferior to low-molecular-weight heparin for venous thromboembolism prevention
Bleeding-Linked Hospitalization Up With Amiodarone in A-Fib
Risk up with amiodarone versus flecainide or sotalol among seniors with atrial fibrillation receiving apixaban or rivaroxaban
Risk for GI Bleed Increased With Hemodialysis Versus Peritoneal Dialysis
Furthermore, use of anticoagulants induces higher incidence of GI bleeding in hemodialysis versus peritoneal dialysis patients
Network Meta-Analysis Compares DOACs to LMWH for Cancer-Linked Thrombosis
Apixaban dominated enoxaparin and edoxaban; rivaroxaban was slightly more effective than apixaban
AHA: Once-Daily Edoxaban Seems Safe for Pediatric Cardiac Patients
Rates of clinically relevant bleeding similar between groups receiving edoxaban or standard-of-care anticoagulation
GI Bleeding Lower With Apixaban Versus Other DOACs in A-Fib
No substantial differences seen for other outcomes or for other direct oral anticoagulant comparisons
